INTRODUCTION {#s1}
============

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality in women worldwide \[[@R1]\]. In the past decade, the incidence and mortality of breast cancer is still gradually increasing \[[@R2]\]. Therapeutic approaches including chemotherapy, radiotherapy, and hormonal therapy are applied in clinical practice for breast treatment. However, the long term survival outcomes are still suboptimal, especially for high-risk individuals \[[@R3]\]. Prognostic factors play important roles in risk estimation and treatment responses prediction for cancer patients. For patients with breast cancer, tumor size, lymph node status, histological grade, and hormone receptor status are commonly used prognostic markers. However, the discriminant efficiency of most prognostic biological factors is still lack of accuracy which reflects the fact that easily available and efficient prognostic variables are required.

Recently, inflammatory responses in tumor microenvironment have been shown to be associated with tumor progression and metastases \[[@R4]\]. Cancer-related inflammatory responses and assist cancer cells in the processes of proliferation, infiltration, neovascularization, and dissemination \[[@R5]\]. Some hematological biomarkers are easy available and costless because they are derived from laboratory tests. There parameters include C-reactive protein (CRP), Glasgow Prognostic Score (GPS), platelet- lymphocyte ratio (PLR), and neutrophil-lymphocyte ratio (NLR). PLR is calculated as platelet counts divided by lymphocyte counts. PLR is reported to be correlated with worse outcomes in different malignant tumors such as colorectal cancer \[[@R6]\], lung cancer \[[@R7], [@R8]\], and gastric cancer \[[@R9], [@R10]\]. Growing evidence also showed that PLR could provide implications for therapeutic modalities selection and prognosis prediction for breast cancer patients \[[@R11]--[@R13]\]. However, the association between PLR and breast cancer prognosis is controversial because relevant studies present different results \[[@R14]--[@R16]\]. These discrepancies could be caused by different study design and small sample sizes. Therefore, in this study, a meta-analysis was performed to reveal the impact of PLR on survival and clinical characteristics in breast cancer.

RESULTS {#s2}
=======

Search results and study characteristics {#s2_1}
----------------------------------------

Initially, 203 records were identified from electronic databases. After removal of duplicates and inspection of titles and/or abstracts, 18 full-text articles were further evaluated. Of these 18 studies, 11 were excluded because they were studies with inadequate data or did not report data on PLR. As a result, 7 studies \[[@R14]--[@R20]\] involving 3,741 patients were enrolled in this study. Detailed search steps were described in Figure [1](#F1){ref-type="fig"}. The sample sizes vary from 62 to 1,435 per study with a median value of 437. Five studies \[[@R14], [@R16], [@R17], [@R19], [@R20]\] were conducted in Asian countries and two studies \[[@R15], [@R18]\] were carried out in non-Asian countries. The cut-off values for PLR ranged from 110 to 292. Six studies \[[@R14]--[@R19]\] reported the correlation between PLR and OS and five studies \[[@R15]--[@R17], [@R19], [@R20]\] investigated the association between PLR and DFS. The NOS scores of all studies were more than 7. General features of the 7 included studies were summarized in Table [1](#T1){ref-type="table"}.
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###### Main characteristics of included studies in meta-analysis

  Study         Year   Region     Sample size   Research period   Stage    Treatment            Cut-off value   Outcome   NOS score
  ------------- ------ ---------- ------------- ----------------- -------- -------------------- --------------- --------- -----------
  Asano         2016   Japan      177           2007--2013        II--IV   Chemotherapy         150             OS, DFS   8
  Azab          2013   USA        437           2004--2006        I--IV    Systemic treatment   185             OS        7
  Cihan         2014   Turkey     350           2005--2010        I--III   Radiotherapy         160             OS, DFS   8
  Gunduz        2015   Turkey     62            2008--2010        I--III   Chemotherapy         200             DFS       8
  Hong          2016   China      487           2009--2010        I--III   Surgery              110             OS, DFS   8
  Koh           2015   Malaysia   1435          2000--2008        I--IV    Systemic treatment   185             OS        7
  Krenn-Pilko   2014   Austria    793           1999--2004        I--III   Systemic treatment   292             OS, DFS   8

Impact of PLR on OS and DFS in breast cancer {#s2_2}
--------------------------------------------

HRs and 95% CIs from 6 studies \[[@R14]--[@R19]\] comprising 3,679 patients were extracted and pooled. Random-effects model was used due to significant heterogeneity (*I*^2^ = 67.3%, P~h~=0.009, Table [2](#T2){ref-type="table"}, Figure [2A](#F2){ref-type="fig"}). The pooled results were HR = 1.55, 95% CI = 1.07 2.25, *p* = 0.022. We also conducted subgroup analysis for further investigation. The results showed that PLR was still an indicator for poor OS in non-Asian patients (HR = 2.36, 95% CI = 1.58--3.52, *p \<* 0.001) and in studies with sample sizes \> 400 (HR = 1.67, 95% CI = 1.13--2.47, *p* = 0.01). In addition, PLR remains a significant prognostic marker for OS in patients receiving systemic treatment (HR = 1.78, 95% CI = 1.06--2.99, *p* = 0.03) and patients receiving chemotherapy (HR = 2.82, 95% CI = 1.09--7.26, *p* = 0.032). A total of 5 studies \[[@R15]--[@R17], [@R19], [@R20]\] containing 1,869 patients reported the prognostic significance of PLR on DFS. The pooled results showed that PLR was significantly associated with worse DFS (HR = 1.73, 95% CI = 1.3--2.3, *p \<* 0.001) and the heterogeneity was not significant (*I*^2^ = 40.5%, *P*~h~ = 0.151, Table [2](#T2){ref-type="table"}, Figure [2B](#F2){ref-type="fig"}). Subgroup analysis demonstrated that PLR was connected with shorter DFS in both Asian patients (HR = 1.72, 95% CI = 1.06--2.8, *p* = 0.027) and non-Asian countries (HR = 2.03, 95% CI = 1.03--4.01, *p* = 0.042) and in studies with patients amount \> 400 (HR = 1.87, 95% CI = 1.27--2.76, *p* = 0.002). Moreover, high PLR also indicates poor DFS in patients who receive chemotherapy (HR = 2.6, 95% CI = 1.47--4.61, *p* = 0.001), surgery (HR = 1.8, 95% CI = 1.12--2.89, *p* = 0.016) and systemic treatment (HR = 2.03, 95% CI = 1.03--4.01, *p* = 0.042). These results indicated that high PLR was significantly associated with poor OS and DFS in patients with breast cancer.
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###### Meta-analysis of PLR and OS, DFS

  Factors              No. of studies   No. of patients   HR (95% CI)         *p*        Effects model   Heterogeneity   
  -------------------- ---------------- ----------------- ------------------- ---------- --------------- --------------- -------
  Overall for OS       6                3,679             1.55 (1.07--2.25)   0.022      Random          67.3            0.009
  Region                                                                                                                 
  Asian                4                2,449             1.26 (0.85--1.85)   0.251      Random          52.2            0.099
  Non-Asian            2                1,230             2.36 (1.58--3.52)   \< 0.001   Fixed           0               0.427
  Treatment                                                                                                              
  Systemic treatment   3                2,665             1.78 (1.06--2.99)   0.03       Random          76.6            0.014
  Chemotherapy         1                177               2.82 (1.09--7.26)   0.032      --              --              --
  Radiotherapy         1                350               0.7 (0.37--1.31)    0.264      --              --              --
  Surgery              1                487               1.42 (0.76--2.68)   0.273      --              --              --
  Sample size (*n*)                                                                                                      
  \> 400               4                3,152             1.67 (1.13--2.47)   0.01       Random          64.8            0.036
  \< 400               2                527               1.34 (0.34--5.23)   0.674      Random          82.7            0.016
  Overall for DFS      5                1,869             1.73 (1.3--2.3)     \< 0.001   Fixed           40.5            0.151
  Region                                                                                                                 
  Asian                4                1,076             1.72 (1.06--2.8)    0.027      Random          53.6            0.091
  Non-Asian            1                793               2.03 (1.03--4.01)   0.042      --              --              --
  Treatment                                                                                                              
  Chemotherapy         2                239               2.6 (1.47--4.61)    0.001      Fixed           0               0.708
  Radiotherapy         1                350               0.9 (0.49--1.66)    0.736      --              --              --
  Surgery              1                487               1.8 (1.12--2.89)    0.016      --              --              --
  Systemic treatment   1                793               2.03 (1.03--4.01)   0.042      --              --              --
  Sample size (*n*)                                                                                                      
  \> 400               2                1,280             1.87 (1.27--2.76)   0.002      Fixed           0               0.773
  \< 400               3                589               1.73 (0.81--3.72)   0.158      Random          68.4            0.042

OS = overall survival; DFS = disease-free survival.

Relationships between PLR and clinicopathological features {#s2_3}
----------------------------------------------------------

We explored the correlation between PLR and 6 clinicopathological parameters. As shown in Figure [3](#F3){ref-type="fig"}, PLR was shown to be associated with human epidermal growth factor receptor-2 (HER-2) positivity (OR = 1.48, 95% CI = 1.2--1.83, *p* \< 0.001). However, the pooled data demonstrated that PLR was not significantly correlated with other 5 clinicopathological factors including lymph node metastasis (OR=1.23, 95% CI = 0.88--1.73, *p* = 0.229), unclear grade (OR=0.94, 95% CI = 0.48--1.84, *p* = 0.859), estrogen receptor (ER) status (OR=0.93, 95% CI = 0.78--1.11, *p* = 0.42), progesterone receptor (PR) status (OR= 0.88, 95% CI = 0.73--1.06, *p* = 0.168) or AJCC stage (OR=1.51, 95% CI = 0.85--2.67, *p* = 0.158).
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Publication bias {#s2_4}
----------------

We performed Begg\'s funnel plot and Egger\'s linear regression test to estimate potential publication bias in this meta-analysis. The *p* values for OS were 0.452 (Begg\'s test) and 0.418 (Egger\'s test) and *p* values for DFS were 0.221 (Begg\'s test) and 0.583 (Egger\'s test). The results showed that there was no significant publication bias in our study.

DISCUSSION {#s3}
==========

In this meta-analysis containing 7 studies, the combined results showed that PLR was a significant biomarker for poor OS (HR = 1.55, 95% CI = 1.07--2.25, *p* = 0.022) and DFS (HR = 1.73, 95% CI = 1.3--2.3, *p* \< 0.001). Subgroup analyses disclosed that elevated PLR could predict worse OS in Asian populations and poor DFS in both Asian and non-Asian patients. In addition, PLR was also in association with HER-2 positivity (OR = 1.48, 95% CI = 1.2--1.83, *p \<* 0.001). Taken all these into consideration, PLR could serve as a convenient and reliable marker for breast cancer prognostication.

Tumor-promoting inflammation is an emerging hallmark of cancer \[[@R21]\]. Systemic inflammatory responses can facilitate tumor progression in almost every single step including initiation, progression, and metastasis \[[@R5]\]. On the one hand, current evidence shows that platelets can guard tumor cells from immune elimination and are involved in development of aggressive tumor behaviors \[[@R22]\]. In addition, platelets can promote tumor-cell transendothelial migration and metastasis through the mediation of P2Y~2~ receptor \[[@R23]\]. Platelets can secret a variety of growth factors including platelet derived growth factor (PDGF) \[[@R24]\], platelet-activating factor (PAF) \[[@R25]\], and vascular endothelium growth factor (VEGF) \[[@R26]\], which could further support tumor growth, angiogenesis and metastasis \[[@R27]\]. Therefore, increased platelet counts have negative effects on patient survival. On the other hand, lymphocytes play an important role in tumor-derived inflammatory responses \[[@R28]\]. Lymphocytes have an antitumor activity by inducing cytotoxic cell death and inhibiting tumor proliferation \[[@R4]\]. Several studies reported that the increased infiltration of lymphocytes in tumor tissue predicted better survival outcomes in cancer patients \[[@R29], [@R30]\].

Notably, previous studies showed that high PLR was in association with poor survival in other tumors including non-small cell lung cancer \[[@R31]\], colorectal cancer \[[@R32]\], gastric cancer \[[@R33]\], and various solid tumors \[[@R34], [@R35]\] by performing meta-analysis. Our results regarding breast cancer were in line with results of studies on other cancer forms \[[@R31], [@R33], [@R36]\]. We noted that breast cancer was investigated merely as a small proportion of all cancer types in previous meta-analyses with at most two primary studies included \[[@R34], [@R35]\]. There was no study focusing on the prognostic value of PLR on breast cancer through meta-analysis. To our knowledge, the present study is the first meta-analysis to investigate the relationship between PLR and breast cancer.

There are several limitations to our study. First, this meta-analysis was performed based on the pooled HRs and 95% CIs from eligible studies other than detailed individual information. Thus, potential bias may still exist. Second, the cut-off values for PLR were different in included studies, because they identified the cut-off values according to various criteria. Although the patient groups were divided into PLR-high and PLR-low populations, the stratifications may change when the cut-off changes. Therefore, a standard and uniform cut-off value defining high PLR is needed.

In conclusion, this meta-analysis demonstrated that high PLR was an indicator of worse OS and DFS in breast cancer. Moreover, PLR was related to HER-2 positivity. Further high-quality and large-scale studies are required to determine the validation of other results.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

This study was conducted referring to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@R37]\]. Relevant studies were thoroughly searched from PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) up to August, 2016. The search strategy included following keywords: "PLR", "platelet lymphocyte ratio", "breast cancer", "breast carcinoma", and "breast neoplasms" \[MeSH Terms\]. References in all relevant articles were also checked to identify potentially relevant studies. There was no language restriction.

Selection criteria {#s4_2}
------------------

Inclusion criteria were as follows: (1) PLR was measured pretreatment on basis of blood tests; (2) the diagnosis of breast cancer established by pathological examination; (3) reported a cut-off value for PLR; (4) reported the associations between PLR and survival outcomes; (5) sufficient data were provided to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Exclusion criteria in this study were as follows: (1) reviews, case reports, conference abstracts and letters; (2) studies with insufficient data; (3) animal studies. Two independent investigators (YYZ and WS) evaluated the candidate studies and disagreements were resolved by discussing with a third investigator (JLY).

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two investigators (YYZ and WS) independently performed the data extraction from eligible studies. The following information was extracted: first author\'s name, year of publication, country, sample size, research period, survival outcomes, cut-off value, and clinicalpathological characteristics. The qualities of included studies were evaluated using Newcastle--Ottawa Quality Scale (NOS) assessment \[[@R38]\]. Three parts including selection, comparability, and outcomes were evaluated in this scale with a maximum score of 9. Studies with scores ≥ 7 were considered as high-quality studies.

Statistical analysis {#s4_4}
--------------------

HR and 95% CI were used as the effective measures to estimate the relationships of PLR and overall survival (OS) and disease-free survival (DFS). If possible, HRs and 95% CIs were directly extracted from included studies, or they were computed based on methods by Tierney et al \[[@R39]\]. Odds ratio (OR) and 95% CI were utilized to evaluate the associations between PLR and clinicopathological factors. Heterogeneity among studies was assessed by Cochran\'s *Q* test and the Higgins\' *I*^2^ statistic. A *P* value for heterogeneity \< 0.05 and/or *I*^2^ \> 50% indicated significant heterogeneity, and a random-effects model was used; otherwise, a fixed-effects model was applied. Publication bias was tested by Begg\'s funnel plots and Egger\'s linear regression test. *P* \< 0.05 was considered as statistically significant. All analyses were performed by using STATA version 12.0 (Stata Corporation, College Station, TX, USA).
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